Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Tekedereli, Ibrahim ^a   Alpay, S Neslihan ^a   Tavares, Clint D J ^b   Cobanoglu, Zehra E ^a   Kaoud, Tamer S ^b   Sahin, Ibrahim ^a   Sood, Anil K ^a   Lopez Berestein, Gabriel ^a   Dalby, Kevin N ^b   Ozpolat, Bulent ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; ELONGATION FACTOR 2 KINASE; FOCAL ADHESION KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYC PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE P60; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ELONGATION FACTOR 2 KINASE; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, SRC; HUMANS; MICE; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE;

EUKARYOTA;

EID: 84864094070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041171     Document Type: Article

References (75)

1. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808.
2. (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942.
3. Hait WN, Wu H, Jin S, Yang JM, (2006) Elongation factor-2 kinase: its role in protein synthesis and autophagy. Autophagy 2: 294-296.
4. Nairn AC, Bhagat B, Palfrey HC, (1985) Identification of calmodulin-dependent protein kinase III and its major Mr 100,000 substrate in mammalian tissues. Proc Natl Acad Sci U S A 82: 7939-7943.
5. Tavares CDJ, O'Brien JP, Abramczyk O, Devkota AK, Shores KS, et al. (2012) Calcium/Calmodulin Stimulates the Autophosphorylation of Elongation Factor 2 Kinase on Thr-348 and Ser-500 To Regulate Its Activity and Calcium Dependence. Biochemistry 51: 2232-2245.
6. Nairn AC, Palfrey HC, (1987) Identification of the major Mr 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2. Journal of Biological Chemistry 262: 17299-17303.
7. Chafouleas JG, Pardue RL, Brinkley BR, Dedman JR, Means AR, (1981) Regulation of intracellular levels of calmodulin and tubulin in normal and transformed cells. Proc Natl Acad Sci U S A 78: 996-1000.
8. Parmer TG, Ward MD, Yurkow EJ, Vyas VH, Kearney TJ, et al. (1998) Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br J Cancer 79: 59-64.
9. Bagaglio DM, Hait WN, (1994) Role of calmodulin-dependent phosphorylation of elongation factor 2 in the proliferation of rat glial cells. Cell Growth Differ 5: 1403-1408.
10. Nilsson A, Nygard O, (1995) Phosphorylation of eukaryotic elongation factor 2 in differentiating and proliferating HL-60 cells. Biochim Biophys Acta 1268: 263-268.
11. Parmer TG, Ward MD, Hait WN, (1997) Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase III, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Differ 8: 327-334.
12. Proud CG, (2007) Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 403: 217-234.
13. Chen Z, Gopalakrishnan SM, Bui MH, Soni NB, Warrior U, et al. (2011) 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): A cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. The Journal of biological chemistry.
14. Ryazanov AG, (2002) Elongation factor-2 kinase and its newly discovered relatives. FEBS letters 514: 26-29.
15. Browne GJ, Finn SG, Proud CG, (2004) Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 279: 12220-12231.
16. Browne GJ, Finn SG, Proud CG, (2004) Stimulation of the AMP-activated Protein Kinase Leads to Activation of Eukaryotic Elongation Factor 2 Kinase and to Its Phosphorylation at a Novel Site, Serine 398. Journal of Biological Chemistry 279: 12220-12231.
17. Connolly E, Braunstein S, Formenti S, Schneider RJ, (2006) Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Molecular and cellular biology 26: 3955-3965.
18. Yang J, Yang JM, Iannone M, Shih WJ, Lin Y, et al. (2001) Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer research 61: 4010-4016.
19. Wu H, Yang JM, Jin S, Zhang H, Hait WN, (2006) Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer research 66: 3015-3023.
20. Wu H, Zhu H, Liu DX, Niu TK, Ren X, et al. (2009) Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer research 69: 2453-2460.
21. Cheng Y, Ren X, Zhang Y, Patel R, Sharma A, et al. (2011) eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Research 71: 2654-2663.
22. Zhang L, Zhang Y, Liu XY, Qin ZH, Yang JM, (2011) Expression of elongation factor-2 kinase contributes to anoikis resistance and invasion of human glioma cells. Acta pharmacologica Sinica 32: 361-367.
23. Zhang Y, Cheng Y, Zhang L, Ren X, Huber-Keener KJ, et al. (2011) Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression. Biochemical and biophysical research communications 414: 129-134.
24. Cheng Y, Li H, Ren X, Niu T, Hait WN, et al. (2010) Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS ONE 5: e9715.
25. Boyce M, Py BF, Ryazanov AG, Minden JS, Long K, et al. (2008) A pharmacoproteomic approach implicates eukaryotic elongation factor 2 kinase in ER stress-induced cell death. Cell death and differentiation 15: 589-599.
26. Devkota AK, Tavares CDJ, Warthaka M, Abramczyk O, Marshall KD, et al. (2012) Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase by NH125: Evidence of a Common in Vitro Artifact. Biochemistry 51: 2100-2112.
27. Hannon GJ, Rossi JJ, (2004) Unlocking the potential of the human genome with RNA interference. Nature 431: 371-378.
28. Spagnou S, Miller AD, Keller M, (2004) Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43: 13348-13356.
29. Ozpolat B, Sood AK, Lopez-Berestein G, (2010) Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 267: 44-53.
30. Abramczyk O, Tavares CDJ, Devkota AK, Ryazanov AG, Turk BE, et al. (2011) Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli. Protein Expression and Purification 79: 237-244.
31. Casamayor A, Morrice NA, Alessi DR, (1999) Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. The Biochemical journal 342 (Pt 2): 287-292.
32. Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, et al. (2008) Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy 4: 669-679.
33. Plumb JA, (1999) Cell sensitivity assays: clonogenic assay. Methods Mol Med 28: 17-23.
34. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, et al. (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer research 65: 6910-6918.
35. Gavrieli Y, Sherman Y, Ben-Sasson SA, (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. The Journal of cell biology 119: 493-501.
36. Engel LW, Young NA, (1978) Human breast carcinoma cells in continuous culture: a review. Cancer Res 38: 4327-4339.
37. Gildish I, Manor D, David O, Sharma V, Williams D, et al. (2012) Impaired associative taste learning and abnormal brain activation in kinase-defective eEF2K mice. Learning & memory 19: 116-125.
38. Calberg U, Nilsson A, Skog S, Palmquist K, Nygard O, (1991) Increased activity of the eEF-2 specific, Ca2+ and calmodulin dependent protein kinase III during the S-phase in Ehrlich ascites cells. Biochem Biophys Res Commun 180: 1372-1376.
39. Parmer TG, Ward MD, Yurkow EJ, Vyas VH, Kearney TJ, et al. (1999) Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br J Cancer 79: 59-64.
40. Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, et al. (2007) Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 5: 95-108.
41. Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ, (1994) Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 9: 3635-3645.
42. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, et al. (2001) Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20: 1688-1702.
43. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, et al. (2010) Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Molecular cancer therapeutics 9: 1180-1187.
44. Ozpolat B, Sood AK, Lopez-Berestein G, (2010) Nanomedicine based approaches for the delivery of siRNA in cancer. Journal of internal medicine 267: 44-53.
45. Cobleigh MA, (2011) Other options in the treatment of advanced breast cancer. Seminars in oncology 38: S11-16.
46. Shaw LM, (2005) Tumor cell invasion assays. Methods Mol Biol 294: 97-105.
47. Finn RS, (2008) Targeting Src in breast cancer. Ann Oncol 19: 1379-1386.
48. Summy JM, Gallick GE, (2006) Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 12: 1398-1401.
49. Biscardi JS, Belsches AP, Parsons SJ, (1998) Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog 21: 261-272.
50. Luttrell DK, Lee A, Lansing TJ, Crosby RM, Jung KD, et al. (1994) Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci U S A 91: 83-87.
51. Roskoski RF Jr, (2004) Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun 324: 1155-1164.
52. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, et al. (1994) Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 14: 1680-1688.
53. Mitra SK, Schlaepfer DD, (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. Current opinion in cell biology 18: 516-523.
54. Moon DO, Kim MO, Heo MS, Lee JD, Choi YH, et al. (2009) Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. Arch Pharm Res 32: 1351-1360.
55. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
56. Arora S, Yang JM, Hait WN, (2005) Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer research 65: 3806-3810.
57. Devkota AK, Tavares CD, Warthaka M, Abramczyk O, Marshall KD, et al. (2012) Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2 Kinase (eEF-2K) by NH125: Evidence for a Common in vitro Artifact. Biochemistry.
58. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
59. Ozpolat B, Tekedereli I, Akar U, Lopez-Berestein G, (2010) Targeted silencing of Bcl-2 by systemic adminstration of liposomal siRNA inhibits growth of Bcl-2 expressing breast cancer tumors in vivo through apoptosis and authophagy. Proceedings of the American Association for Cancer Research (AACR 2010) (Abstract #51084).
60. Alkarain A, Jordan R, Slingerland J, (2004) p27 deregulation in breast cancer: prognostic significance and implications for therapy. Journal of mammary gland biology and neoplasia 9: 67-80.
61. Liao DJ, Thakur A, Wu J, Biliran H, Sarkar FH, (2007) Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog 13: 93-158.
62. Dang CV, Kim JW, Gao P, Yustein J, (2008) The interplay between MYC and HIF in cancer. Nat Rev Cancer 8: 51-56.
63. Scheetz AJ, Nairn AC, Constantine-Paton M, (2000) NMDA receptor-mediated control of protein synthesis at developing synapses. Nat Neurosci 3: 211-216.
64. Park S, Park JM, Kim S, Kim J-A, Shepherd JD, et al. (2008) Elongation Factor 2 and Fragile X Mental Retardation Protein Control the Dynamic Translation of Arc/Arg3.1 Essential for mGluR-LTD. Neuron 59: 70-83.
65. Weatherill DB, McCamphill PK, Pethoukov E, Dunn TW, Fan X, et al. (2011) Compartment-specific, differential regulation of eukaryotic elongation factor 2 and its kinase within Aplysia sensory neurons. Journal of Neurochemistry 117: 841-855.
66. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J, (2005) Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 280: 10964-10973.
67. Parkin N, Darveau A, Nicholson R, Sonenberg N, (1988) cis-acting translational effects of the 5′ noncoding region of c-myc mRNA. Mol Cell Biol 8: 2875-2883.
68. Shahid R, Bugaut A, Balasubramanian S, (2010) The BCL-2 5′ untranslated region contains an RNA G-quadruplex-forming motif that modulates protein expression. Biochemistry 49: 8300-8306.
69. Ma XM, Blenis J, (2009) Molecular mechanisms of mTOR-mediated translational control. Nature reviews Molecular cell biology 10: 307-318.
70. Rosenwald IB, Setkov NA, Kazakov VN, Chen JJ, Ryazanov AG, et al. (1995) Transient inhibition of protein synthesis induces expression of proto-oncogenes and stimulates resting cells to enter the cell cycle. Cell Prolif 28: 631-644.
71. Chen CY, Fang HY, Chiou SH, Yi SE, Huang CY, et al. (2011) Sumoylation of eukaryotic elongation factor 2 is vital for protein stability and anti-apoptotic activity in lung adenocarcinoma cells. Cancer science 102: 1582-1589.
72. Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S, Hirata E, et al. (2009) Overexpression of eukaryotic elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. International journal of oncology 34: 1181-1189.
73. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, et al. (1994) Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54: 1812-1817.
74. Liao DJ, Dickson RB, (2000) c-Myc in breast cancer. Endocrine-related cancer 7: 143-164.
75. Wilson GR, Cramer A, Welman A, Knox F, Swindell R, et al. (2006) Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 95: 1410-1414.